Teva asks Fed Circ for ‘skinny label’ redo

Teva Pharmaceuticals has once again petitioned the US Court of Appeals for the Federal Circuit to reconsider its decision in a dispute over generic drug labelling which held that the drugmaker infringed GlaxoSmithKline’s (GSK) Coreg heart drug (Carvedilol).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Split Fed Circuit refuses Teva 'skinny label' ruling review

14 February 2022 A split US Court of Appeals for the Federal Circuit has declined to rehear a generic drug labelling dispute between Teva and GlaxoSmithKline.

Americas

Fed Circ panel reviews $235m GSK award over ‘skinny’ Teva generic

25 February 2021 A panel of the US Court of Appeals for the Federal Circuit has considered for a second time the $235 million award to GlaxoSmithKline after Teva Pharmaceuticals was found to have infringed its Coreg heart drug.

Americas

Teva urges Fed Circuit to save skinny label law from ‘nullification’

3 December 2020 Teva has urged the US Court of Appeals for the Federal Circuit to rehear its dispute with GlaxoSmithKline en banc, claiming that if the decision is upheld, “every skinny-labelled generic is at risk”.

More on this story

Americas

Split Fed Circuit refuses Teva 'skinny label' ruling review

14 February 2022 A split US Court of Appeals for the Federal Circuit has declined to rehear a generic drug labelling dispute between Teva and GlaxoSmithKline.

Americas

Fed Circ panel reviews $235m GSK award over ‘skinny’ Teva generic

Americas

Teva urges Fed Circuit to save skinny label law from ‘nullification’

More on this story

Americas

Split Fed Circuit refuses Teva 'skinny label' ruling review

14 February 2022 A split US Court of Appeals for the Federal Circuit has declined to rehear a generic drug labelling dispute between Teva and GlaxoSmithKline.

Americas

Fed Circ panel reviews $235m GSK award over ‘skinny’ Teva generic

Americas

Teva urges Fed Circuit to save skinny label law from ‘nullification’